January 18, 2026/
Recognizing AI's profound potential to accelerate development, enhance safety monitoring, and bring effective treatments to patients faster, the two agencies have proactively outlined a principles-based framework designed to...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
Recognizing AI's profound potential to accelerate development, enhance safety monitoring, and bring effective treatments to patients faster, the two agencies have proactively outlined a principles-based framework designed to...
Following a public consultation period (until October 15, 2025), the Algerian Ministry of Health, Ministry of Pharmaceutical Industry, the National Pharmacovigilance and Materiovigilance Centre (CNPM), and...
This document details the safety signals reviewed and the regulatory actions recommended by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) during its meeting in November 2025.
